SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies

A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies


  • Org Study ID: IRB00089583
  • Secondary ID: NCI-2016-01037,Winship3263-16
  • NCT ID: NCT02897375
  • NCT Alias:
  • Sponsor: Emory University - Other
  • Source: Emory University

Brief Summary

This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with treatment. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib with cisplatin or carboplatin may help stop tumor growth in patients with advanced solid tumors.

Detailed Description


PRIMARY OBJECTIVES:

I. Assess the safety and tolerability of palbociclib when administered along with cisplatin
or carboplatin.

II. Establish the recommended phase 2 dose (RP2D) of the tested combinations.

SECONDARY OBJECTIVES:

I. Characterize the pharmacokinetic (PK) profiles of cisplatin, carboplatin.

II. Obtain preliminary evidence of anti-tumor efficacy of the tested combination regimens.

III. Conduct PK/pharmacodynamics (PD) correlative analyses using palbociclib trough
concentration and cyclin-dependent kinase 4 (CDK4) inhibition read-outs in tumor and
surrogate samples collected on course 1 day 22 (C1D22).

IV. Assess potential association between tissue-based biomarkers and efficacy.

OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 arms.

ARM A: Patients receive cisplatin intravenously (IV) over 30-60 minutes on day 1 and
palbociclib orally (PO) once daily (QD) on days 2-22. Treatment repeats every 28 days for up
to 6 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on
days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed for up to 4 weeks.

Overal Status Start Date Phase Study Type
Recruiting Start Date: October 2016 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

Primary Outcome 1 - Time Frame: Study completion, an average of 2 years

Primary Outcome 2 - Measure: Incidence of dose limiting toxicities defined as grade 3 or higher toxicity

Primary Outcome 2 - Time Frame: Up to 4 weeks

Primary Outcome 3 - Measure: Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin

Primary Outcome 3 - Time Frame: Study completion, an average of 2 years

Condition:

  • Solid Neoplasm
  • Stage III Pancreatic Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIA Non-Small Cell Lung Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIB Non-Small Cell Lung Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Stage IVA Pancreatic Cancer
  • Stage IVB Pancreatic Cancer
  • Sarcoma
  • Colorectal Cancer
  • Head and Neck Cancer
  • Cancer of Unknown Primary
  • Bladder Cancer
  • Ovarian Cancer

Eligibility

Criteria:
Inclusion Criteria:

- Patients must have histologically or cytologically confirmed solid organ malignancy

- Patients enrolled in the expansion cohort must have histologically or cytologically
confirmed squamous non-small cell lung cancer (NSCLC), breast or pancreaticobiliary
tract cancer

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) with
conventional techniques or as ≥ 10 mm (≥ 1 cm) with spiral computed tomography (CT)
scan, magnetic resonance imaging (MRI), or calipers by clinical exam

- Leukocytes ≥ 3,000/mL

- Absolute neutrophil count ≥ 1,500/mL

- Platelets ≥ 100,000/mL

- Hemoglobin ≥ 10 g/dL

- Total bilirubin ≤ 1.5 × institutional upper limit of normal (except for patients with
Gilbert disease)

- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/
alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 ×
institutional upper limit of normal (up to 5 X upper limit of normal [ULN] for
patients with liver metastasis)

- Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min/1.73
m² for patients with creatinine levels above institutional normal

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation; should a woman become pregnant or suspect she is
pregnant while she or her partner is participating in this study, she should inform
her treating physician immediately; men treated or enrolled on this protocol must also
agree to use adequate contraception prior to the study, for the duration of study
participation, and for 6 months after completion of study drug administration

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had cytotoxic anticancer chemotherapy or immune checkpoint inhibitor
within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or palliative radiation
within 2 weeks (stereotactic radiation therapy [SRS] for brain metastasis within 48
hours) prior to entering the study or those who have not recovered from adverse events
due to agents administered more than 4 weeks earlier

- Patients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic
indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to
discontinue such agents within 2 weeks prior to starting treatment

- Oral targeted therapy within five days or five half-lives, whichever is longer, prior
to initiating protocol therapy treatment

- Patients who are receiving any other investigational agents

- Use of strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors and inducers

- Patients with symptomatic uncontrolled brain metastases are excluded; (patients with
stable treated or asymptomatic untreated brain metastasis not requiring
glucocorticoids are allowed)

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to palbociclib, carboplatin or cisplatin

- Concurrent administration of strong inducers and inhibitors of CYP3A enzyme or CYP3A
substrates with narrow therapeutic window

- Uncontrolled intercurrent illness including, but not limited to:

- Ongoing or active infection requiring intravenous antibiotics at the time of
treatment initiation

- Symptomatic congestive heart failure (requiring hospital stay within the last 6
months)

- Myocardial infarction within the last 6 months

- Unstable angina pectoris, cardiac arrhythmia

- Psychiatric illness

- Social situations or circumstances that would limit compliance with study requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with palbociclib

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Taofeek Owonikoko, MD, PhD

Role: Principal Investigator

Affiliation: Emory University

Overall Contact

Name: Taofeek Owonikoko, MD, PhD

Phone: 404-778-4383

Email: towonik@emory.edu

Location

Facility Status Contact
Emory University/Winship Cancer Institute
Atlanta, Georgia 30322
United States
Recruiting Nakita Brown
404-616-9850
nlbrown@emory.edu